- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Natasha B Leighl
Radical Treatment of Stage II Non-small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes.
Clin Lung Cancer. 2017 Jun 21;:
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
Oncotarget. 2017 Jun 28;:
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
Front Oncol. 2017;7:113
Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.
Ther Adv Med Oncol. 2017 Jun;9(6):405-414
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.
Nat Genet. 2017 Jun 12;:
J Thorac Oncol. 2017 May 27;:
Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
Lung Cancer. 2017 Jul;109:78-88
Lung Cancer. 2017 Jul;109:137-144
Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer.
Lung Cancer. 2017 Jul;109:117-123
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group